Related references
Note: Only part of the references are listed.Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis
Binod Dhakal et al.
JAMA ONCOLOGY (2018)
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Philippe Moreau et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States
Christopher G. Pelligra et al.
CLINICAL THERAPEUTICS (2017)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
Philippe Moreau et al.
LEUKEMIA & LYMPHOMA (2016)
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Xavier Leleu et al.
BLOOD (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
